ABBV - AbbVie Inc.
| Previous close | 96.83 |
| Open | 97.36 |
| Bid | 98.96 x 1300 |
| Ask | 98.97 x 800 |
| Day's range | 96.92 - 99.56 |
| 52-week range | 62.55 - 100.69 |
| Volume | 3,378,405 |
| Avg. volume | 10,110,949 |
| Market cap | 174.296B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | 17.50 |
| EPS (TTM) | 5.65 |
| Earnings date | 31 Jul 2020 |
| Forward dividend & yield | 4.72 (4.87%) |
| Ex-dividend date | 14 Jul 2020 |
| 1y target est | 104.44 |
- Zacks
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
- Zacks
AbbVie (ABBV) Gets FDA Nod for Another Botox Label Expansion
AbbVie (ABBV) wins the FDA nod for an expanded use of Botox to treat spasticity in pediatric patients aged two years and above including those with lower limb spasticity caused by cerebral palsy.
- Zacks
Is AbbVie (ABBV) Stock Outpacing Its Medical Peers This Year?
Is (ABBV) Outperforming Other Medical Stocks This Year?
- Zacks
6 Stocks to Wade Through the Spike in Coronavirus Cases
The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.
- Motley Fool
Better Buy: AbbVie vs. Biogen
AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year. As we will see below, Biogen has encountered some severe headwinds recently, which explains its poor stock-price performance.
- Zacks
4 Value Stocks to Buy in a Recovering Economy
Vitals of financial markets and the U.S. economy are recovering gradually, making way for value stocks to gain pace ahead.
- Motley Fool
3 Best-Performing Dividend Aristocrats in the First Half of 2020: Are They Buys Now?
Exceptional dividend track records. Exceptional stock performances in the first six months of the year.
- Simply Wall St.
Shareholders Of AbbVie (NYSE:ABBV) Must Be Happy With Their 75% Return
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
- Zacks
4 Reasons to Own AbbVie Stock as Coronavirus Woes Linger
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
- Motley Fool
Got $5,000? Buy These 3 High-Yield Dividend Stocks That Are Money Machines
You can do just that with dividend stocks. Others are on such shaky ground that their dividends are in jeopardy. If you've got $5,000 to invest, here are three high-yield dividend stocks that are flat-out money machines.
- Zacks
AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Motley Fool
Better Coronavirus Stock: Eli Lilly or AbbVie?
Eli Lilly (NYSE: LLY) is a veteran in the pharmaceutical community and has been in business for over 140 years. AbbVie (NYSE: ABBV) is a relative newcomer and was established back in 2013 after spinning off parent organization Abbott Laboratories. Last year was a good one for Eli Lilly.
- Motley Fool
5 High-Yield Dividend Stocks to Watch
One of the places they've found cash returns is in dividend stocks, particularly those that offer a relatively high payout. Fortunately, some high-yield dividend stocks remain well-positioned to sustain their dividends. AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013.
- Zacks
Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety
All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...
- Zacks
What Makes AbbVie (ABBV) a New Strong Buy Stock
AbbVie (ABBV) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
Zacks.com featured highlights include: Kroger, AbbVie, W.W. Grainger, West Pharmaceutical Services and Taiwan Semiconductor Manufacturing Company
- Zacks
Ollie's Bargain Outlet, Designer Brands, AbbVie, Microsoft and Lockheed Martin highlighted as Zacks Bull and Bear of the Day
Ollie's Bargain Outlet, Designer Brands, AbbVie, Microsoft and Lockheed Martin highlighted as Zacks Bull and Bear of the Day
- Zacks
3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety
Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...
- Zacks
Signs That Your Trading Will Ruin Your Retirement - June 30, 2020
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
- Zacks
5 Great Dividend Growth Stocks Amid Market Volatility
The second wave of coronavirus infections has flared up volatility and made investors scurry for safety and regular income. This has resulted in higher appeal for dividend investing.
- Zacks
Wall Street Braces for Higher Bouts of Volatility: 5 Safe Picks
As markets remain disturbed, investing in stocks that provide excellent risk-adjusted returns seems judicious. The best way to go about doing this is by creating a portfolio of low-beta stocks.
- Zacks
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
